Search Immortality Topics:

Page 9«..891011..2030..»


Global Nanoparticles in Biotechnology and Pharmaceuticals Market Insights, Growth Analysis, Forecasts to 2025 : Roche, GE Healthcare, Merck, Novartis…

Posted: December 8, 2019 at 9:41 am

The global "Nanoparticles in Biotechnology and Pharmaceuticals Market" market gives a huge platform for different firms, manufacturers, and organizations, such as, Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire that compete among each other for offering reliable products and satisfactory services to their clients and hold considerable shares over the market. The report also provides evaluated data of the market and its rivals on a global basis.

Apply here for the sample copy of the report @: https://www.reportsbuzz.com/request-for-sample.html?repid=71531

Furthermore, The report presents a detailed segmentation Fullerenes, Liquid Crystals, Liposomes, Nanoshells, Quantum dots, Superparamagnetic nanoparticles, Market Trend by Application Biotechnology, Pharmaceutical of the global market based on technology, product type, application, and various processes and systems.The Nanoparticles in Biotechnology and Pharmaceuticals market report explains the key growth factors and limitations that remarkably influence the market, and also provides the information about the previous and current status of the Nanoparticles in Biotechnology and Pharmaceuticals market at global level.

The global Nanoparticles in Biotechnology and Pharmaceuticals market report incorporates an upcoming estimated impact over the market by the new laws and regulations launched by the government. The market report formation requires detailed research and analysis to realize the market growth; and different scientific strategies, including SWOT analysis to get the information suitable to evaluate the upcoming monetary variations associated to the current situation and growth pattern of the market.

Read Detailed Index of full Research Study at:: https://www.reportsbuzz.com/71531/global-nanoparticles-in-biotechnology-and-pharmaceuticals-market-outlook/

The global Nanoparticles in Biotechnology and Pharmaceuticals market report offers comprehensive important points that significantly affect the growth of the Nanoparticles in Biotechnology and Pharmaceuticals market at a global level. It gives the present status and also future growth pattern of the market. The report is created after detailed research and exhaustive investigation of the market development in different sectors that requires theoretical analysis, technology-based ideas, and its validity. The report includes the description about the factors that considerably enhance and downgrade the growth of the market profound explanation of the market's past data; alongside the current investigated data, and forecast the development trend of the Nanoparticles in Biotechnology and Pharmaceuticals market. The global Nanoparticles in Biotechnology and Pharmaceuticals market report also provides a hypothetical study related to the monetary insecurities about demand and supply.

There are 15 Chapters to display the Global Nanoparticles in Biotechnology and Pharmaceuticals market

Chapter 1, Definition, Specifications and Classification of Nanoparticles in Biotechnology and Pharmaceuticals, Applications of Nanoparticles in Biotechnology and Pharmaceuticals, Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Nanoparticles in Biotechnology and Pharmaceuticals, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Nanoparticles in Biotechnology and Pharmaceuticals Segment Market Analysis (by Type);Chapter 7 and 8, The Nanoparticles in Biotechnology and Pharmaceuticals Segment Market Analysis (by Application) Major Manufacturers Analysis of Nanoparticles in Biotechnology and Pharmaceuticals ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Fullerenes, Liquid Crystals, Liposomes, Nanoshells, Quantum dots, Superparamagnetic nanoparticles, Market Trend by Application Biotechnology, Pharmaceutical;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Nanoparticles in Biotechnology and Pharmaceuticals ;Chapter 12, Nanoparticles in Biotechnology and Pharmaceuticals Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Nanoparticles in Biotechnology and Pharmaceuticals sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @: https://www.reportsbuzz.com/inquiry-for-buying.html?repid=71531

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Sorry! The Author has not filled his profile.

See the original post here:
Global Nanoparticles in Biotechnology and Pharmaceuticals Market Insights, Growth Analysis, Forecasts to 2025 : Roche, GE Healthcare, Merck, Novartis...

Recommendation and review posted by G. Smith

Orgenesis and Theracell to launch point-of-care cell and gene therapy centers in HYGEIA Group"s hospitals – Proactive Investors USA & Canada

Posted: December 8, 2019 at 9:41 am

CEO Vered Caplan says the move would enable the development and delivery of cell and gene therapies onsite at HYGEIA's hospitals in Greece

Inc (), a developer of advanced cell therapies, revealed Friday that it struck a strategic partnership agreement between the Theracell joint venture and the large HYGEIA Group which runs three hospitals in Greece.

In a statement, the Germantown, Maryland-based company said that under the terms of the agreement, the joint venture will implement point-of-care cell therapy platform for clinical development and commercialization of cell and gene therapies within the HYGEIA Groups network of hospitals in Greece.

and TheraCell Advanced Biotechnology earlier formed a joint venture to advance point-of-care platform in Greece, the Balkan region and some Middle Eastern countries.

The point-of-care platform is designed to collect, process and supply cells within the patient care setting for various treatments.

The main goal is to reduce the cost and complexity of supplying cell and gene therapies, said , as well as boostquality by integrating automated processing units and proprietary technologies.

Significantly, HYGEIA is the first hospital network in the region to implement Orgenesis point-of-care cell therapy platform. The partnership aims to provide the HYGEIA Group with resources to advance clinical development and deliver personalized, advanced therapies across its network for a range of diseases in oncology, hematology, orthopedics, nephrology, dermatology and diabetes.

This partnership with the HYGEIA Group further validates the significant value proposition of our point-of-care platform, as it enables the development and delivery of cell and gene therapies onsite at hospitals, said Orgenesis CEO Vered Caplan.

We believe this platform has the potential to transform the cell and gene therapy market, by bringing life-saving therapies to market in a much more time and cost-effective manner, she added.

The Orgenesis boss said Theracell had proved to be an ideal partner with extensive experience and capabilities in autologous cell therapy and regenerative medicine, and strong operations in Greece and relationships in the region.

We are in active discussions to establish PoCare locations and partnerships with hospitals and healthcare networks in other countries and regions across the world, said Caplan.

Greeces HYGEIA Group operates three hospitals with a capacity of 1,261 beds, 52 operating rooms, 19 delivery rooms and 10 intensive care units.

HYGEIA Group CEO Andreas Kartapanis said thanks to the partnership with Theracell and Orgenesis it would be the first hospital network in Greece to provide advanced cell and gene therapies.

We believe this partnership will provide us a strong competitive advantage in this rapidly developing field. More importantly, this partnership will benefit patients that will now have greater access to these important therapies, said Kartapanis.

For the fiscal third quarter ended September 30, Orgenesis generated meaningful revenue, over $1 million, through its rapidly advancing point-of-care cellular therapy platform.

Meanwhile, TheraCell has experience in the isolation, processing and application of adipose-derived stem cells, as well as somatic cells. It has developed a patented platform for tissue engineering and cell therapies in the areas of dermatology, articular cartilage defects, and chronic kidney injury.

Contact Uttara Choudhury at[emailprotected]

Follow her onTwitter:@UttaraProactive

See the article here:
Orgenesis and Theracell to launch point-of-care cell and gene therapy centers in HYGEIA Group"s hospitals - Proactive Investors USA & Canada

Recommendation and review posted by G. Smith

Those Who Purchased Puma Biotechnology (NASDAQ:PBYI) Shares Five Years Ago Have A 96% Loss To Show For It – Yahoo Finance

Posted: December 8, 2019 at 9:41 am

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held Puma Biotechnology, Inc. (NASDAQ:PBYI) for five years would be nursing their metaphorical wounds since the share price dropped 96% in that time. And we doubt long term believers are the only worried holders, since the stock price has declined 68% over the last twelve months. Furthermore, it's down 31% in about a quarter. That's not much fun for holders.

We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway.

Check out our latest analysis for Puma Biotechnology

Given that Puma Biotechnology didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

NasdaqGS:PBYI Income Statement, December 6th 2019

This free interactive report on Puma Biotechnology's balance sheet strength is a great place to start, if you want to investigate the stock further.

Puma Biotechnology shareholders are down 68% for the year, but the market itself is up 18%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 48% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See more here:
Those Who Purchased Puma Biotechnology (NASDAQ:PBYI) Shares Five Years Ago Have A 96% Loss To Show For It - Yahoo Finance

Recommendation and review posted by G. Smith

Boosting food production through biotechnology – The Nation Newspaper

Posted: December 8, 2019 at 9:41 am

Experts are advocating the use of biosciences to bring about economic transformation. They believe science-based agricultural products and processes can eliminate hunger, malnutrition and boost produce resilience to climate change-related impacts. One of the approaches is biotechnology, which is the use of scientific tools and techniques to boost food production, DANIEL ESSIET reports.

Nigeria has the largest population in Africa, and it is growing at 3.2 per cent a year.

According to the United Nations (UN) projections for West Africa, Nigeria will be the worlds third most populous country by 2050. Similarly, the United States Census Bureau said there will be an estimated 402 million people in Nigeria in 2050.

For analysts, it is going to be a serious challenge feeding an amazing growing population if new agricultural technologies are not adopted to boost production.

Agricultural experts have recommended that the government should be more proactive in using science, technology and innovationespecially biotechnologyto address food security challenges facing the continent. Hence, there has been increased campaign for biotechnology.

Experts believe biotechnology innovations can enhance productivity and boost food security.

Commonly, biotechnology involves the use of tools and techniques involving biological or chemical processes to boost food production. It is a broad category involving many types of technology and science, including breeding, genetics, microbiome research, and animal health and nutrition.

Agribusinesses have been innovating in biotech for many decades to increase and protect crop yields with fertiliser, crop protection products such as pesticides and improved seeds.

With the population of Nigeria projected to reach 402 million by 2050 and agriculture struggling to adapt to climate change, the pressure to meet the increasing demand for staple foods, including soya beans and maize, has raised interest in safe biotechnologys ability to boost yield.

One of the farmers pushing for safe use of biotechnology is Innocent Mokidi. He is Chief Executive, Brote Urban Vegetable Farm and Processing Limited. He runs large farms in Abuja and Nassarawa State.

He has managed farms where improved soya beans and maize varieties have outperformed conventional seeds per hectare. He has seen maize yielding 10 tonnes per hectare.

While he has made a huge success in agriculture, he is concerned about many Nigerian farmers that eke out a living from small plots of poor soils. Also, crop yields from such farmlands are stagnant and poor .

The only way they can grow more food and have a surplus for sale, according to him, is for the government to promote safe biotechnology in form of improved plant seeds.

As staple foods provide vital nutrients and health benefits, making up close to two-thirds of the nations food intake, Mokidi urged the government and the private sector to tackle food insecurity through improved nutrient-rich, high-yielding varieties and sustainable agronomic practices, ensuring that those who most depend on agriculture have enough to make a living and feed their families.

He wants scientists to develop technologies that can contribute to food security and prosperity among farmers.

In addition to achieving higher yields and reducing pesticide use, farmers such as Mokidi want maize free of the mold that produces aflatoxin, a naturally occurring cancer-causing toxin frequently found in grain products.

A senior lecturer, Department of Crop Science and Biotechnology, Faculty of Agriculture & Veterinary, Imo State University (IMSU) Prof. Martin Onuh, said there was need to deploy biotechnology innovations to make life better for farmers through seeds that produce higher than usual yields with fewer inputs.

He advocated the adoption of responsible breeding technologies to meet most of the Sustainable Development Goals (SDG) targets linked to hunger, food security and nutrition.

In Nigeria, biotechnology tools have been used to improve crops. Maize, sorghum, cowpea and groundnut are the major crops covered by plant breeding activities.

A senior scientist at the International Institute of Tropical Agriculture (IITA), Dr Chiedozie Egesi, is leading a research team developing and releasing several improved varieties of cassava, including one fortified with vitamin A. They are part of the Next Generation Cassava Breeding project (NextGen Cassava), an initiative funded by the Bill & Melinda Gates Foundation and UK Aid from the United Kingdom.

Researchers engaged in the project, which began in 2012 and runs through 2023, have made major strides in understanding cassavas genome and flowering. This has allowed them to shorten the time it takes to develop hardier new cassava varieties that improve yields.

All over Africa, experts are calling for investment in biotechnology. One of them is the President of Alliance for a Green Revolution in Africa (AGRA) Dr. Agnes Kalibata .She has urged intensification of collective efforts towards the eradication of hunger and malnutrition by 2025.

Kalibata said AGRAs mission is to develop practical solutions to significantly boost farm productivity and incomes for the poor while safeguarding the environment, working across all key aspects of the African agricultural value chain from seeds, soil health and water to markets and agricultural education.

AGRAs work primarily focuses on smallholder farmers men and women who typically cultivate staple crops on two hectares or less. In the new strategy for 2017-2021, AGRA is supporting 11 African countries and 30 million smallholder farm households (150 million individuals) to increase their incomes and improve their food security.

This year, AGRA, Syngenta and Syngenta Foundation for Sustainable Agriculture (SFSA) have signed an agreement to work together towards their shared vision of transforming Africas agriculture.

Specifically, the three institutions will work to give farmers access to: yield-enhancing technologies including high-quality seeds, good agriculture practices, and post-harvest management.

Another crusader on the continental front is the Director, Agriculture School, UM6P Agriculture School, and Prof Aziz Yasri. He said there was a need for universities in Africa to work together to build capacities in agricultural technology and to support skills development for employability and entrepreneurship.

He said UM6P is willing to work with other universities to promote business prospect in agriculture while applying and utilising science, technology and innovation (STI).

To promote increased use of biotechnology to boost food production, the university has received funding for agriculture research to help farmers on the continent.

UM6P and OCP, Moroccos phosphates and Fertiliser Company, have signed an agreement with Spanish company Fertinagro Biotech, part of the Trvalis Group to use biotechnology to grow more food.

The goal is to train researchers who subsequently serve in companies that provide sustainable solutions for the development of African and world agriculture and livestock.

The agreement will involve the training of researchers who will seek and develop innovation projects in fields such as sustainability and development, based on actions that promote the circular economy and, at the same time, lead to a well-being for the environment and sustainability.

The collaboration between the institutions also includes connections with Spains leading universities in the fields of agriculture, recycling economy and agro-biosciences.

Under the agreement, OCP will support the project by providing opportunities for practical experience and on the ground testing.

UM6P Secretary-General, Hicham El Habti explained that universitys pioneering role among world-renowned universities in the field. Our objective is to consolidate Moroccos frontline position in R&D, in a unique partnership-based approach and boosting skills training, relevant for the future of Africa, he said.

Read the original post:
Boosting food production through biotechnology - The Nation Newspaper

Recommendation and review posted by G. Smith

We’re Not Worried About B.R.A.I.N. Biotechnology Research and Information Network’s (ETR:BNN) Cash Burn – Yahoo Finance

Posted: December 8, 2019 at 9:41 am

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.

So, the natural question for B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

View our latest analysis for B.R.A.I.N. Biotechnology Research and Information Network

A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at June 2019, B.R.A.I.N. Biotechnology Research and Information Network had cash of 15m and such minimal debt that we can ignore it for the purposes of this analysis. Looking at the last year, the company burnt through 5.4m. That means it had a cash runway of about 2.8 years as of June 2019. Notably, however, analysts think that B.R.A.I.N. Biotechnology Research and Information Network will break even (at a free cash flow level) before then. If that happens, then the length of its cash runway, today, would become a moot point. You can see how its cash balance has changed over time in the image below.

XTRA:BNN Historical Debt, December 2nd 2019

It was fairly positive to see that B.R.A.I.N. Biotechnology Research and Information Network reduced its cash burn by 39% during the last year. And considering that its operating revenue gained 45% during that period, that's great to see. We think it is growing rather well, upon reflection. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

We are certainly impressed with the progress B.R.A.I.N. Biotechnology Research and Information Network has made over the last year, but it is also worth considering how costly it would be if it wanted to raise more cash to fund faster growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash to fund growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Since it has a market capitalisation of 175m, B.R.A.I.N. Biotechnology Research and Information Network's 5.4m in cash burn equates to about 3.1% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

Story continues

It may already be apparent to you that we're relatively comfortable with the way B.R.A.I.N. Biotechnology Research and Information Network is burning through its cash. For example, we think its cash runway suggests that the company is on a good path. And even though its cash burn reduction wasn't quite as impressive, it was still a positive. Shareholders can take heart from the fact that analysts are forecasting it will reach breakeven. Taking all the factors in this report into account, we're not at all worried about its cash burn, as the business appears well capitalized to spend as needs be. While we always like to monitor cash burn for early stage companies, qualitative factors such as the CEO pay can also shed light on the situation. Click here to see free what the B.R.A.I.N. Biotechnology Research and Information Network CEO is paid..

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See original here:
We're Not Worried About B.R.A.I.N. Biotechnology Research and Information Network's (ETR:BNN) Cash Burn - Yahoo Finance

Recommendation and review posted by G. Smith

Unity Biotechnology Inc (NASDAQ:UBX) Short Interest Update – Riverton Roll

Posted: December 8, 2019 at 9:41 am

Unity Biotechnology Inc (NASDAQ:UBX) saw a significant increase in short interest in November. As of November 15th, there was short interest totalling 4,910,000 shares, an increase of 5.8% from the October 31st total of 4,640,000 shares. Currently, 23.0% of the shares of the stock are sold short. Based on an average daily volume of 278,100 shares, the days-to-cover ratio is currently 17.7 days.

Several large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC acquired a new position in Unity Biotechnology during the third quarter worth approximately $45,000. Bank of Montreal Can grew its position in Unity Biotechnology by 164,400.0% during the second quarter. Bank of Montreal Can now owns 4,935 shares of the companys stock worth $47,000 after buying an additional 4,932 shares in the last quarter. Aperio Group LLC bought a new position in Unity Biotechnology during the 2nd quarter worth $50,000. Squarepoint Ops LLC bought a new position in Unity Biotechnology in the 3rd quarter valued at about $82,000. Finally, Ellington Management Group LLC bought a new position in Unity Biotechnology in the second quarter valued at approximately $103,000. 35.56% of the stock is currently owned by institutional investors and hedge funds.

Shares of UBX opened at $7.19 on Friday. The stock has a 50 day simple moving average of $6.98 and a 200 day simple moving average of $7.32. Unity Biotechnology has a 52-week low of $5.61 and a 52-week high of $17.46. The firm has a market capitalization of $330.32 million, a PE ratio of -2.83 and a beta of 0.02.

Unity Biotechnology (NASDAQ:UBX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.54) earnings per share for the quarter, missing analysts consensus estimates of ($0.49) by ($0.05). As a group, research analysts anticipate that Unity Biotechnology will post -2 EPS for the current fiscal year.

Several equities research analysts have recently commented on UBX shares. Cantor Fitzgerald reissued an overweight rating on shares of Unity Biotechnology in a research note on Thursday, October 17th. Zacks Investment Research downgraded Unity Biotechnology from a hold rating to a sell rating in a report on Saturday, October 12th. Finally, Mizuho restated a buy rating and set a $33.00 target price on shares of Unity Biotechnology in a report on Monday, November 18th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $19.50.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.

Featured Article: Day Trading

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

More:
Unity Biotechnology Inc (NASDAQ:UBX) Short Interest Update - Riverton Roll

Recommendation and review posted by G. Smith


Page 9«..891011..2030..»